Table 3

Three-Year Clinical Outcomes

Zotarolimus-Eluting Stent (n = 1,502)Biolimus-Eluting Stent (n = 1,497)Hazard Ratio (95% CI)p Value
0–36 months
 Major adverse cardiac events128 (8.6)144 (9.6)0.90 (0.71–1.14)0.36
 Death114 (7.6)114 (7.6)1.01 (0.78–1.30)0.96
 Cardiac death41 (2.7)51 (3.4)0.81 (0.54–1.22)0.31
Myocardial infarction62 (4.1)70 (4.7)0.89 (0.63–1.25)0.49
 Target myocardial infarction40 (2.7)38 (2.5)1.06 (0.68–1.65)0.80
 Any revascularization239 (16.0)249 (16.6)0.96 (0.80–1.14)0.63
 Target vessel revascularization115 (7.7)121 (8.1)0.95 (0.74–1.23)0.70
 Target lesion revascularization81 (5.4)83 (5.5)0.98 (0.72–1.33)0.90
 Definite or probable stent thrombosis19 (1.3)18 (1.2)1.06 (0.56–2.02)0.86
 Definite stent thrombosis15 (1.0)17 (1.1)0.89 (0.44–1.77)0.73
 Early (<30 days)5 (0.3)1 (0.1)
 Late (31 days to 12 months)4 (0.3)6 (0.4)
 Very late (12–36 months)6 (0.4)10 (0.7)
12–36 months
 Major adverse cardiac events50 (3.6)68 (4.8)0.74 (0.51–1.07)0.11
 Death64 (4.4)74 (5.1)0.87 (0.62–1.22)0.42
 Cardiac death19 (1.3)25 (1.7)0.77 (0.42–1.39)0.38
 Myocardial infarction31 (2.1)39 (2.7)0.79 (0.49–1.27)0.33
 Target myocardial infarction18 (1.2)23 (1.5)0.79 (0.42–1.45)0.44
 Any revascularization85 (6.3)77 (5.8)1.09 (0.80–1.49)0.56
 Target vessel revascularization50 (3.5)50 (3.5)1.00 (0.68–1.48)1.00
 Target lesion revascularization30 (2.1)36 (2.5)0.84 (0.52–1.36)0.48
 Definite or probable stent thrombosis7 (0.5)10 (0.7)0.70 (0.27–1.85)0.48
 Definite stent thrombosis6 (0.4)10 (0.7)0.60 (0.22–1.66)0.33

Values are n (%) unless otherwise indicated. Two-sided confidence intervals have been used for all endpoints.

  • Cardiac death, myocardial infarction not clearly attributable to a non-target lesion, and clinically indicated target lesion revascularization.

  • Myocardial infarction not clearly attributable to a non-target lesion.

  • Academic Research Consortium definition.